Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti C A, Bevilacqua G
Department of Oncology, University of Pisa, Italy.
J Natl Cancer Inst. 1997 Jun 18;89(12):881-6. doi: 10.1093/jnci/89.12.881.
Tumors acquire nutrients that are essential for continued growth and an avenue for dissemination to the rest of the body by inducing angiogenesis (i.e., the formation of new blood vessels). Preliminary studies involving a number of different kinds of cancer have indicated that an assessment of tumor angiogenesis may be useful in predicting disease outcome.
In a prospective study, we evaluated the relationship between tumor angiogenesis and survival for 407 patients with non-small-cell lung carcinoma who were treated with potentially curative surgery.
The study population consisted of 360 male and 47 female patients who underwent surgery consecutively at the Department of Surgery, University of Pisa, Italy, from March 1991 through December 1994. Follow-up lasted through February 1996, with a median follow-up for living patients of 29 months (range, 15-60 months). An anti-CD34 monoclonal antibody, which is specific for endothelial cells, and standard immunohistochemical techniques were used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel counts; the counts for single, high-power microscopic fields (magnification x250) in the three most intense areas of blood vessel growth for each sample were averaged. The median microvessel count in this series was 20, and the counts were categorized as follows: 1) low versus high (< or =20 versus >20 microvessels) or 2) in five categories (1-10, 11-20, 21-30, 31-40, and > or =41 microvessels). Disease-free and overall survival during follow-up were assessed. Kaplan-Meier survival curves were modeled in a univariate analysis of patient and tumor characteristics; the Cox proportional hazards model was used in multivariate analysis. Reported P values are two-sided.
In the univariate analysis, patients with larger tumors (P for trend <.00001), a more advanced tumor stage (P for trend <.00001), a greater degree of regional lymph node involvement (P for trend <.00001), or more vascularized tumors (high versus low microvessel count, P<.00001) experienced significantly reduced overall survival. When microvessel counts were analyzed in five categories, a highly significant trend (P<.00001) toward worse prognosis was observed with increasing tumor vascularity. In multivariate analysis, tumor microvessel count (P<.00001), tumor size (P = .0006), and regional lymph node status (P<.00001) retained independent prognostic value with respect to overall survival; among these variables, tumor microvessel count, considered as a continuous variable, was the most important, with a relative hazard of death of 8.38 (95% confidence interval = 4.19-16.78) associated with the highest microvessel counts.
An evaluation of tumor angiogenesis may be useful in the postsurgical staging of patients with non-small-cell lung carcinoma and in identifying subsets of patients who may benefit from different postsurgical treatments.
肿瘤通过诱导血管生成(即新血管的形成)来获取持续生长所需的营养物质,并为扩散至身体其他部位提供途径。涉及多种不同类型癌症的初步研究表明,评估肿瘤血管生成可能有助于预测疾病预后。
在一项前瞻性研究中,我们评估了407例接受根治性手术治疗的非小细胞肺癌患者的肿瘤血管生成与生存之间的关系。
研究对象包括1991年3月至1994年12月在意大利比萨大学外科连续接受手术的360例男性和47例女性患者。随访持续至1996年2月,存活患者的中位随访时间为29个月(范围15 - 60个月)。使用针对内皮细胞的抗CD34单克隆抗体和标准免疫组织化学技术来测量肿瘤样本中的血管生成。血管生成通过微血管计数进行量化;对每个样本血管生长最活跃的三个高倍显微镜视野(放大倍数×250)中的计数进行平均。本系列研究中的中位微血管计数为20,计数分类如下:1)低与高(≤20与>20个微血管)或2)分为五类(1 - 10、11 - 20、21 - 30、31 - 40以及≥41个微血管)。评估随访期间的无病生存期和总生存期。在对患者和肿瘤特征的单因素分析中构建Kaplan - Meier生存曲线;多因素分析使用Cox比例风险模型。报告的P值为双侧。
在单因素分析中,肿瘤较大(趋势P <.00001)、肿瘤分期较晚(趋势P <.00001)、区域淋巴结受累程度较高(趋势P <.00001)或肿瘤血管化程度较高(高微血管计数与低微血管计数相比,P <.00001)的患者总生存期显著降低。当将微血管计数分为五类进行分析时,随着肿瘤血管化程度增加,观察到预后显著变差的高度显著趋势(P <.00001)。在多因素分析中,肿瘤微血管计数(P <.00001)、肿瘤大小(P =.0006)和区域淋巴结状态(P <.00001)在总生存期方面保留独立的预后价值;在这些变量中,被视为连续变量的肿瘤微血管计数最为重要,微血管计数最高时死亡相对风险为8.38(95%置信区间 = 4.19 - 16.78)。
评估肿瘤血管生成可能有助于非小细胞肺癌患者的术后分期,并识别可能从不同术后治疗中获益的患者亚组。